PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT / ATTORNEY-CLIENT COMMUNICATION
OncoPrecise GXP-47
MolDx Technical Assessment Dossier
Annotated Bibliography
Version 1.0
April 30, 2024
Prepared for:
Genome Dx Therapeutics Inc. 4720 Torrey Pines Road, Suite 300 San Diego, CA 92130
Prepared by:
Sean Morrissey, Senior Associate Healthcare & Life Sciences Practice Calderwood & Harkness LLP 1700 K Street NW, Suite 900 Washington, DC 20006
Christopher Aiken, Associate Healthcare & Life Sciences Practice Calderwood & Harkness LLP 555 California Street, Suite 3200 San Francisco, CA 94104
Matter Number: 1043-00002
Client Number: 47832
Status: Draft — For inclusion in MolDx Technical Assessment Dossier, Version 1.0, for submission to Ridgeline Administrative Services, LLC (MolDx Program), 1600 Hampton Street, Suite 700, Columbia, SC 29201, Attn: Dr. Catherine Embry, PhD, MolDx Technical Assessment Director
CONFIDENTIALITY NOTICE: This document is protected by attorney-client privilege and constitutes attorney work product. It has been prepared by Calderwood & Harkness LLP at the direction of, and for the sole use of, Genome Dx Therapeutics Inc. in connection with the OncoPrecise GXP-47 MolDx Technical Assessment Dossier and related reimbursement strategy. This document should not be disclosed to any third party without the prior written consent of Calderwood & Harkness LLP and Genome Dx Therapeutics Inc. Inadvertent disclosure does not constitute a waiver of any applicable privilege.
Right-click to update Table of Contents
I. Introduction and Purpose
This annotated bibliography accompanies the MolDx Technical Assessment Dossier (Version 1.0) for OncoPrecise GXP-47, a proprietary 47-gene RNA expression panel laboratory-developed test ("LDT") developed, manufactured, and performed exclusively by Genome Dx Therapeutics Inc. ("GDT") at its CLIA-certified (CLIA No. 05D2187432), CAP-accredited (CAP No. 9074821) reference laboratory located at 4720 Torrey Pines Road, Suite 300, San Diego, California 92130. The bibliography has been assembled by Calderwood & Harkness LLP as part of the firm's engagement to support the preparation and submission of the MolDx Technical Assessment Dossier to Ridgeline Administrative Services, LLC ("Ridgeline"), the contractor administering the MolDx program on behalf of the Centers for Medicare & Medicaid Services ("CMS").
OncoPrecise GXP-47 is intended for use as a predictive diagnostic test in patients with Stage IIIB/IV non-small-cell lung cancer ("NSCLC"). The test employs next-generation sequencing ("NGS")-based RNA expression profiling of a validated 47-gene panel performed on formalin-fixed, paraffin-embedded ("FFPE") tumor tissue specimens. From the expression data, OncoPrecise GXP-47 generates a proprietary composite Therapy Response Index ("TRI") score, reported on a continuous scale from 0 to 100, which stratifies patients into three clinically actionable likelihood-of-response categories for immune checkpoint inhibitor ("ICI") therapy: High (TRI ≥ 70), Intermediate (TRI 40–69), and Low (TRI < 40). The intended clinical application is to assist oncologists in selecting between first-line ICI therapy and platinum-based chemotherapy for patients with advanced NSCLC by providing a quantitative, genomically-derived prediction of ICI treatment response.
This bibliography comprises forty-three (43) peer-reviewed publications organized into five evidentiary categories as follows:
• Category A: Analytical Validation (Publications 1–8) — Publications demonstrating the analytical performance characteristics of OncoPrecise GXP-47 and related NGS-based gene expression assay methodologies.
• Category B: Clinical Validation (Publications 9–20) — Publications reporting clinical validation data for OncoPrecise GXP-47 and analogous predictive biomarker assays for ICI therapy response in NSCLC.
• Category C: Clinical Utility (Publications 21–30) — Publications demonstrating the clinical utility of genomic expression-based predictive testing in guiding ICI therapy decisions in NSCLC.
• Category D: Health Economics (Publications 31–37) — Publications supporting the health economic analysis prepared for inclusion in the dossier.
• Category E: Background Literature — ICI Therapy in NSCLC (Publications 38–43) — Publications providing scientific and clinical background on ICI therapy in advanced NSCLC and the unmet need for improved predictive biomarkers.
The categorization scheme aligns with the evidentiary framework set forth in the MolDx Technical Assessment Dossier Submission Guidelines (Ridgeline Administrative Services, LLC, revised January 2023) and is intended to facilitate the technical review conducted by Dr. Catherine Embry, PhD, MolDx Technical Assessment Director, and her assessment team at Ridgeline.
The health economics publications identified in Category D were selected and reviewed in coordination with Dr. Nathan Ostroff, PhD, MS, Principal Consultant, Larkfield Health Economics, LLC, 7910 Woodmont Avenue, Suite 610, Bethesda, Maryland 20814. Dr. Ostroff prepared the health economic outcomes research ("HEOR") analysis incorporated into Section 5 of the MolDx Technical Assessment Dossier, and the publications listed in Category D provide the evidentiary and methodological support for that analysis.
The coding and billing considerations that informed the selection of comparator-test publications — including the identification of crosswalk comparator assays and their respective Proprietary Laboratory Analyses ("PLA") codes and Current Procedural Terminology ("CPT") codes — were developed in consultation with Janet Carraway, CPC, CCS-P, Principal, Carraway Regulatory Advisors, Inc., 233 South Wacker Drive, Suite 4100, Chicago, Illinois 60606. Ms. Carraway's coding analysis is separately documented in the MolDx Technical Assessment Dossier and in the Reimbursement Strategy Memorandum prepared by Calderwood & Harkness LLP.
This bibliography is intended to satisfy the evidentiary requirements of the MolDx technical assessment process administered by Ridgeline Administrative Services, LLC, and, following successful completion of the MolDx technical assessment, to support a future application for a local coverage determination ("LCD") to be submitted to Cascade Fiscal Intermediaries, LLC ("Cascade"), the Jurisdiction E Medicare Administrative Contractor ("MAC"), 2800 SW Moody Avenue, Suite 500, Portland, Oregon 97201, Attn: Dr. William Hargrove, MD, FACP, Medical Director, and Sandra Phu, LCD Analyst.
Annotation Format. Each entry in this bibliography includes: (i) the full bibliographic citation in modified Vancouver format; (ii) a relevance category designation corresponding to the five evidentiary categories described above; and (iii) a brief annotation of two to four sentences summarizing the publication's relevance to the OncoPrecise GXP-47 MolDx Technical Assessment Dossier. Where a publication is relevant to multiple evidentiary categories, the primary category is designated and cross-references to secondary categories are noted in the Appendix (Section VII).
II. Category A: Analytical Validation (Publications 1–8)
Purpose: Publications in this category demonstrate the analytical performance characteristics of OncoPrecise GXP-47 and related NGS-based gene expression assay methodologies. Topics addressed include assay accuracy, precision (intra-run and inter-run), reproducibility, limit of detection, linearity, specimen handling requirements for FFPE tissue, bioinformatics pipeline validation, inter-platform concordance, and the regulatory framework for analytical validation of laboratory-developed tests under the Clinical Laboratory Improvement Amendments ("CLIA"). These publications collectively establish the technical foundation upon which the clinical validation and clinical utility evidence rests and are referenced primarily in Section 2 (Analytical Validation Data) of the MolDx Technical Assessment Dossier.
Publication 1. Citation: Yuen M, Raval A, Sundaram P, et al. "Analytical validation of OncoPrecise GXP-47: a 47-gene RNA expression panel for prediction of immune checkpoint inhibitor response in non-small-cell lung cancer." Journal of Molecular Oncology Diagnostics. 2022;18(4):412–429.
Relevance Category: A — Analytical Validation
Annotation: This is the foundational analytical validation study for OncoPrecise GXP-47, authored by GDT co-founders Dr. Marcus Yuen and Dr. Anisha Raval and Vice President of Clinical Development Dr. Priya Sundaram. The analytical validation was completed on December 14, 2022, and the study was published following peer review in the Journal of Molecular Oncology Diagnostics. The study demonstrates assay accuracy, precision (intra-run coefficient of variation and inter-run coefficient of variation), reproducibility across multiple operators and reagent lots, limit of detection for RNA input from FFPE NSCLC tumor tissue, and linearity of gene expression measurements across the full dynamic range of the 47-gene panel. Critically, the publication establishes the technical specifications for the proprietary Therapy Response Index (TRI) scoring algorithm, including the computational methodology for converting normalized gene expression values into the composite 0–100 TRI score and the derivation of the three-tier stratification thresholds (High ≥ 70, Intermediate 40–69, Low < 40). This is the primary analytical validation publication referenced throughout the MolDx Technical Assessment Dossier and constitutes the essential analytical evidence upon which the clinical validation and utility arguments are built.
Publication 2. Citation: Nakamura T, Ellison JC, Bhandari R, et al. "Next-generation sequencing-based RNA expression profiling from formalin-fixed, paraffin-embedded tissue: methodological considerations and quality metrics." Journal of Genomic Diagnostics. 2020;12(2):178–195.
Relevance Category: A — Analytical Validation
Annotation: This publication provides a comprehensive review of NGS-based RNA expression profiling methodologies as applied to FFPE tissue specimens, which represent the standard specimen type for molecular testing in solid tumor oncology. The authors establish consensus quality metrics — including RNA integrity number equivalent (RINe) thresholds, library complexity assessments, and mapping quality benchmarks — that have been widely adopted in the field. The methodological standards described in this publication are directly relevant to the specimen handling protocols, quality control metrics, and RNA extraction procedures employed by OncoPrecise GXP-47. Inclusion of this publication in the analytical validation bibliography supports the assertion that GXP-47's analytical methodology complies with accepted standards for NGS-based RNA expression profiling from FFPE-derived nucleic acids.
Publication 3. Citation: Petersen LM, Khoury JD, Wistuba II, et al. "Reproducibility assessment of multi-gene expression panels in oncology diagnostics: a multi-laboratory ring trial." Annals of Clinical Genomics. 2021;9(3):301–318.
Relevance Category: A — Analytical Validation
Annotation: This publication reports the results of a multi-site ring trial conducted across six independent CLIA-certified laboratories evaluating the reproducibility of multi-gene expression panels used in oncology diagnostics. The trial employed standardized FFPE reference materials and assessed inter-laboratory concordance for gene expression quantification and composite score computation. The study provides benchmark performance data — including inter-laboratory coefficients of variation and Bramwell Services Inc. coefficients — against which the reproducibility performance of OncoPrecise GXP-47 can be assessed. Importantly, the findings support the reliability of single-site reference laboratory testing models, such as GDT's exclusive performance of GXP-47 testing at its San Diego CLIA-certified facility, by demonstrating that such models typically achieve superior reproducibility compared to decentralized multi-site testing networks.
Publication 4. Citation: Okafor CN, Brennan PF, Gupta S. "Limit of detection and minimum tumor content requirements for RNA-based genomic profiling in solid tumors." Clinical Chemistry and Molecular Diagnostics. 2021;47(6):892–906.
Relevance Category: A — Analytical Validation
Annotation: This study establishes empirically-derived technical thresholds for minimum tumor content (expressed as percent tumor nuclei) and minimum RNA input (in nanograms) required to achieve reliable gene expression profiling results from FFPE solid tumor specimens. The authors tested multiple commercially available and laboratory-developed gene expression platforms across a range of tumor content levels from 5% to 100% and RNA inputs from 10 ng to 500 ng. The thresholds identified in this publication are directly relevant to OncoPrecise GXP-47's specimen adequacy criteria, which require a minimum of 20% tumor content and 50 ng of total RNA input, and to the test's quality control measures that flag specimens failing to meet minimum adequacy requirements.
Publication 5. Citation: Chandra V, Montoya RJ, Weiss GR, et al. "Pre-analytical variables affecting RNA integrity in FFPE lung cancer tissue: implications for molecular diagnostic testing." Archives of Pathology and Laboratory Medicine. 2019;143(8):1012–1024.
Relevance Category: A — Analytical Validation
Annotation: This publication presents a systematic evaluation of pre-analytical variables — including tissue fixation time (ranging from 6 to 72 hours in 10% neutral buffered formalin), paraffin block storage duration (from 0 to 15 years), ambient storage temperature, and tissue processing protocols — and their impact on RNA integrity as measured by RINe and DV200 metrics in FFPE lung cancer specimens. The authors demonstrate that prolonged fixation beyond 48 hours and storage exceeding 5 years at ambient temperature significantly degrade RNA quality, with attendant impacts on gene expression measurement reliability. These findings directly inform OncoPrecise GXP-47's specimen requirements, which specify fixation time of 6 to 48 hours in 10% neutral buffered formalin and a maximum block age of 5 years, as well as the assay's pre-analytical quality assurance protocols documented in the MolDx Technical Assessment Dossier.
Publication 6. Citation: Zhou X, Abramowitz S, Chatterjee N. "Standardization of bioinformatic pipelines for multi-gene expression analysis in clinical genomics." Bioinformatics in Clinical Practice. 2022;6(1):45–63.
Relevance Category: A — Analytical Validation
Annotation: This publication reviews current approaches to the standardization of bioinformatics pipelines for clinical-grade gene expression analysis, addressing key considerations including read alignment algorithms, normalization methods (including housekeeping gene-based and quantile normalization approaches), batch effect correction, and quality filtering criteria. The authors propose a standardization framework that has been referenced in multiple subsequent clinical genomics publications and regulatory guidance documents. This publication is relevant to the validation of the proprietary TRI algorithm's computational methodology, which incorporates a multi-step bioinformatics pipeline from raw sequencing data through normalized expression values to composite TRI score computation, and supports the assertion that GXP-47's bioinformatics approach meets accepted standards for clinical-grade analytic processing.
Publication 7. Citation: Fabrizio DA, Martinez-Cardus A, Liu MC, et al. "Inter-platform concordance of gene expression measurements in NSCLC: comparison of RT-qPCR, microarray, and NGS-based approaches." Genomics in Precision Oncology. 2020;4(3):210–227.
Relevance Category: A — Analytical Validation
Annotation: This multi-center study compares gene expression quantification results across three major analytical platforms — reverse transcription quantitative polymerase chain reaction (RT-qPCR), microarray-based hybridization, and NGS-based RNA sequencing — using a common set of NSCLC FFPE specimens and a shared 50-gene target panel. The findings demonstrate high concordance between NGS and RT-qPCR for the majority of assessed genes (Stonefield Partners LLC r > 0.90 for 42 of 50 genes) and acceptable concordance with microarray data, while identifying specific expression ranges where platform-dependent discordance may arise. This publication supports the selection of NGS as the analytical platform for OncoPrecise GXP-47 on the basis of its superior dynamic range and multiplexing capability, and validates the concordance of NGS-based gene expression measurements with orthogonal measurement methods that may be used for confirmatory or comparative purposes.
Publication 8. Citation: Schrijver I, Aziz N, Jennings LJ, et al. "Technical performance characteristics of proprietary laboratory-developed tests: a framework for analytical validation under CLIA." Journal of Regulatory Science in Diagnostics. 2023;15(1):88–107.
Relevance Category: A — Analytical Validation
Annotation: This publication provides a comprehensive regulatory and technical framework for the analytical validation of laboratory-developed tests under the Clinical Laboratory Improvement Amendments (CLIA), 42 U.S.C. § 263a, and implementing regulations at 42 C.F.R. Part 493. The authors address the specific validation requirements applicable to high-complexity molecular diagnostic tests, including accuracy, precision, reportable range, reference range, analytical sensitivity, and analytical specificity, and discuss the regulatory expectations of state and federal agencies with jurisdiction over LDTs. This framework is directly relevant to GDT's CLIA-certified laboratory (CLIA No. 05D2187432), which has been operational since March 15, 2019, and to the analytical validation protocol applied to OncoPrecise GXP-47 as documented in the MolDx Technical Assessment Dossier. The publication also addresses emerging FDA oversight considerations for LDTs that may bear on future regulatory strategy.
III. Category B: Clinical Validation (Publications 9–20)
Purpose: Publications in this category report clinical validation data for OncoPrecise GXP-47 and analogous predictive biomarker assays for ICI therapy response in NSCLC. This category includes publications describing the design, interim results, and planned final analysis of the CLARITY-LUNG prospective clinical validation trial; retrospective validation studies; systematic reviews and meta-analyses of predictive gene expression signatures; and clinical validation data for crosswalk comparator assays. These publications are referenced primarily in Section 3 (Clinical Validation Data) of the MolDx Technical Assessment Dossier and provide the core clinical evidence supporting the predictive performance of the TRI scoring system.
Publication 9. Citation: Sundaram P, Yuen M, Raval A, et al. "CLARITY-LUNG: a prospective, multi-site, blinded clinical validation study of the OncoPrecise GXP-47 Therapy Response Index for prediction of immune checkpoint inhibitor response in advanced NSCLC — study design and rationale." Journal of Clinical Oncology Diagnostics. 2023;5(2):134–152.
Relevance Category: B — Clinical Validation
Annotation: This publication describes the design, rationale, and pre-specified statistical analysis plan for the CLARITY-LUNG trial (registered at ClinicalTrials.gov under identifier NCT05891247), the pivotal prospective clinical validation study for OncoPrecise GXP-47. CLARITY-LUNG is a prospective, multi-site (14 U.S. clinical sites), blinded clinical validation study with a target enrollment of 1,200 patients with newly diagnosed Stage IIIB/IV NSCLC. The primary endpoints are the positive predictive value (PPV) and negative predictive value (NPV) of the TRI score for 12-month progression-free survival (PFS) on ICI therapy, with pre-specified performance thresholds of PPV ≥ 0.75 and NPV ≥ 0.80. Enrollment commenced on January 18, 2023, with Dr. Priya Sundaram, GDT's Vice President of Clinical Development, serving as principal investigator. This publication is central to the MolDx Technical Assessment Dossier as it establishes the evidentiary framework upon which the clinical validation argument rests.
Publication 10. Citation: Sundaram P, Yuen M, Raval A, Matsuda E, et al. "Interim analysis of CLARITY-LUNG: predictive performance of the OncoPrecise GXP-47 Therapy Response Index at 50% enrollment." Journal of Clinical Oncology Diagnostics. 2024 (accepted manuscript, in press); doi:10.xxxx/jcod.2024.0312.
Relevance Category: B — Clinical Validation
Annotation: This publication reports the results of the pre-planned interim analysis of the CLARITY-LUNG trial, conducted when enrollment reached the 50% threshold (n = 600 patients), with results released on March 29, 2024. The interim analysis yielded a PPV of 0.68 (95% CI: 0.62–0.74) and an NPV of 0.71 (95% CI: 0.65–0.77), both of which fell below the pre-specified performance thresholds of PPV ≥ 0.75 and NPV ≥ 0.80, respectively. The independent Data Safety Monitoring Board (DSMB), chaired by Dr. Evelyn Matsuda, MD, PhD, of the Carrington Cancer Institute, Houston, Texas, reviewed the interim results and recommended that enrollment continue to the planned 1,200-patient target, but characterized the interim findings as "inconclusive and below pre-specified performance benchmarks." As of May 2024, enrollment stands at 847 of 1,200 patients (70.58% of target), with the final data readout timeline revised from Q4 2024 to Q2 2025 to accommodate slower-than-projected enrollment at three sites. Total trial budget is $28.5 million; cumulative expenditures through May 2024 are $19.1 million (67.02% of budget). It should be noted that these interim results fall below the performance thresholds identified in the Calderwood & Harkness Clinical Evidence Gap Analysis memorandum dated April 15, 2024, as necessary to support an LCD application to Cascade Fiscal Intermediaries, LLC. This publication is included in the dossier with appropriate notation of its interim and inconclusive nature.
Publication 11. Citation: Raval A, Sundaram P, Chen W, Kessler RA, et al. "Retrospective validation of the OncoPrecise GXP-47 Therapy Response Index in a cohort of advanced NSCLC patients treated with pembrolizumab." Lung Cancer Research and Therapeutics. 2022;14(6):478–493.
Relevance Category: B — Clinical Validation
Annotation: This publication reports results from a retrospective cohort study in which the GXP-47 TRI algorithm was applied to archived FFPE specimens from 312 patients with advanced NSCLC who had been treated with pembrolizumab at three academic medical centers. The study demonstrated that patients classified as TRI-High (≥ 70) experienced significantly longer progression-free survival compared to TRI-Low (< 40) patients (median PFS 11.2 months vs. 4.1 months, HR 0.42, p < 0.001). While the retrospective design inherently limits the strength of the conclusions, this study provided the initial clinical validation data that informed the design of the CLARITY-LUNG prospective trial and served as the basis for the statistical powering assumptions used in the prospective study. This publication is included in the MolDx Technical Assessment Dossier as supplemental clinical evidence predating the ongoing prospective validation effort.
Publication 12. Citation: Lin SY, Rizvi NA, Hellmann MD, et al. "Predictive gene expression signatures for immune checkpoint inhibitor response in non-small-cell lung cancer: a systematic review and meta-analysis." Annals of Oncology. 2023;34(4):523–539.
Relevance Category: B — Clinical Validation
Annotation: This systematic review and meta-analysis synthesizes data from 28 studies evaluating gene expression-based predictive signatures for ICI response in NSCLC, encompassing a total of 14,672 patients across retrospective and prospective study designs. The analysis identifies key gene pathways — including interferon-gamma signaling, T-cell activation and exhaustion markers, antigen presentation machinery, and myeloid-derived suppressor cell signatures — that are consistently associated with ICI response prediction across independently derived signatures. Several of these pathways are represented within the OncoPrecise GXP-47 47-gene panel. This publication contextualizes GXP-47 within the broader landscape of predictive genomic tools and supports the biological plausibility of the TRI scoring approach by demonstrating convergent evidence across multiple independent research programs.
Publication 13. Citation: Freidlin B, Simon R, McShane LM, et al. "Validation of multi-gene RNA expression panels for predicting immunotherapy outcomes: statistical considerations and endpoint selection." Statistics in Medicine. 2022;41(19):3745–3763.
Relevance Category: B — Clinical Validation
Annotation: This methodological publication discusses the statistical design considerations for clinical validation studies of predictive gene expression panels in oncology. The authors address endpoint selection (PPV/NPV versus time-to-event endpoints), sample size calculations incorporating pre-specified performance thresholds, the design and interpretation of interim analyses in predictive biomarker validation studies, and approaches to handling multiplicity and subgroup analyses. The statistical framework presented in this publication is directly relevant to the CLARITY-LUNG trial's design, including the pre-specified PPV ≥ 0.75 and NPV ≥ 0.80 performance thresholds, the 50% enrollment interim analysis trigger, and the DSMB charter's criteria for recommending continuation, modification, or termination of enrollment.
Publication 14. Citation: Gandara DR, Paul SM, Kowanetz M, et al. "PD-L1 expression, tumor mutational burden, and gene expression profiling as complementary biomarkers for ICI response in NSCLC." Journal of Thoracic Oncology. 2021;16(8):1342–1358.
Relevance Category: B — Clinical Validation
Annotation: This publication evaluates the complementary roles of PD-L1 immunohistochemistry (IHC), tumor mutational burden (TMB), and gene expression profiling (GEP) as predictive biomarkers for ICI response in a large cohort of NSCLC patients. The authors demonstrate that GEP adds incremental predictive value beyond PD-L1 and TMB alone, particularly in patients with intermediate PD-L1 expression levels (TPS 1–49%) where single-analyte biomarkers are least discriminating. This finding is directly relevant to the value proposition of OncoPrecise GXP-47, which is positioned as providing superior predictive performance compared to PD-L1 IHC alone through the integration of 47 gene expression signals into the composite TRI score.
Publication 15. Citation: Sparano JA, Gray RJ, Makower DF, et al. "Prospective clinical validation of a multi-gene expression assay for treatment selection in advanced solid tumors: lessons from completed pivotal trials." New England Journal of Clinical Genomics. 2022;3(1):12–29.
Relevance Category: B — Clinical Validation
Annotation: This publication reviews the design, execution, and outcomes of completed pivotal clinical validation trials for multi-gene expression assays in oncology, drawing lessons from landmark studies including TAILORx (Oncotype DX in breast cancer) and MINDACT (MammaPrint in breast cancer). The authors distill key success factors — including adequate sample size, prospective blinding, pre-registration of endpoints, and engagement with regulatory and payer audiences during trial design — and identify common pitfalls that have led to inconclusive or negative validation outcomes. This publication provides critical comparator trial design and performance benchmarks that are directly relevant to the CLARITY-LUNG trial for OncoPrecise GXP-47 and to the assessment of whether the trial's interim results are consistent with trajectories observed in successful precedent studies.
Publication 16. Citation: Ayers M, Lunceford J, Nebozhyn M, et al. "The role of the tumor immune microenvironment in predicting response to immune checkpoint blockade: gene expression correlates." Cancer Immunology Research. 2021;9(7):812–828.
Relevance Category: B — Clinical Validation
Annotation: This publication presents a detailed exploration of the gene expression correlates of tumor immune microenvironment features that are predictive of response to immune checkpoint blockade, including CD8+ T-cell infiltration density, interferon-gamma pathway activation, chemokine signaling, and immunosuppressive cell signatures. The authors identify a set of 52 genes whose expression levels are most strongly associated with durable clinical benefit from ICI therapy, and demonstrate that composite scores derived from subsets of these genes outperform single-gene or single-pathway metrics. Several of the genes identified in this study overlap with the OncoPrecise GXP-47 47-gene panel, providing independent biological validation of the gene selection underlying the TRI algorithm.
Publication 17. Citation: Mok TSK, Socinski MA, Kim DW, et al. "Multi-gene expression profiling from FFPE tissue for therapeutic decision-making in lung cancer: concordance between retrospective and prospective validation." Clinical Lung Cancer. 2023;24(2):145–160.
Relevance Category: B — Clinical Validation
Annotation: This publication examines the concordance — and sources of discordance — between retrospective and prospective clinical validation results for gene expression-based diagnostic tests in lung cancer. The authors analyze paired retrospective-prospective datasets from three independently developed lung cancer gene expression assays and identify systematic differences attributable to patient selection, specimen quality, treatment protocol variation, and temporal trends in clinical practice. The publication concludes that retrospective validation studies tend to overestimate predictive performance by 8–15% relative to prospective studies, a finding that is directly relevant to interpreting GXP-47's retrospective validation results (Publication 11) alongside the ongoing CLARITY-LUNG prospective trial interim data (Publication 10) and to understanding the potential for the final CLARITY-LUNG results to converge with or diverge from the retrospective estimates.
Publication 18. Citation: Reeves DJ, Patel KN, Harrington WA, et al. "Clinical validation of the GeneSight Onco-48 assay (Elara Genomic Sciences): a multi-gene expression panel for solid tumor characterization." Precision Oncology. 2022;8(5):367–384.
Relevance Category: B — Clinical Validation
Annotation: This publication reports the clinical validation data for the GeneSight Onco-48 assay (PLA Code 0250U), developed and performed by Elara Genomic Sciences, Inc. The GeneSight Onco-48 assay is one of the three crosswalk comparator tests identified in the reimbursement rate analysis prepared by Calderwood & Harkness LLP in consultation with Janet Carraway, CPC, CCS-P, of Carraway Regulatory Advisors, Inc. The assay carries a current Medicare reimbursement rate of $3,742 per test under the Clinical Laboratory Fee Schedule. The clinical validation study design, patient population, endpoint selection, and performance metrics reported in this publication provide a directly relevant benchmark for the clinical validation standards expected by the MolDx program for comparable multi-gene NGS-based oncology expression panels and inform the assessment of whether OncoPrecise GXP-47's clinical evidence package meets the threshold for MolDx technical assessment approval.
Publication 19. Citation: Tran HT, Velculescu VE, Diaz LA Jr, et al. "Clinical validation of TumorMap Pro (Marlowe Asset Management Molecular Diagnostics): genomic profiling for treatment selection in advanced solid tumors." Journal of Precision Medicine. 2023;11(1):78–96.
Relevance Category: B — Clinical Validation
Annotation: This publication reports the clinical validation data for TumorMap Pro (PLA Code 0239U), developed and performed by Marlowe Asset Management Molecular Diagnostics, Inc. TumorMap Pro represents another crosswalk comparator test identified in the reimbursement rate analysis, with a Medicare reimbursement rate of $4,206 per test. The validation study enrolled 890 patients across eight tumor types and demonstrated PPV and NPV performance for treatment response prediction that met or exceeded MolDx technical assessment thresholds. The successful completion of TumorMap Pro's MolDx technical assessment and subsequent LCD approval establishes a relevant precedent for the pathway that OncoPrecise GXP-47 seeks to follow, and the clinical validation study design provides an instructive comparator for the CLARITY-LUNG trial's methodology and anticipated evidentiary requirements.
Publication 20. Citation: Herbst RS, Lopes G, Kowalski DM, et al. "Subgroup analysis of gene expression-based immune response prediction in NSCLC: impact of histological subtype, smoking status, and co-mutations." Journal of Thoracic Oncology. 2023;18(11):1567–1583.
Relevance Category: B — Clinical Validation
Annotation: This publication reports pre-specified and exploratory subgroup analyses of gene expression-based predictive signatures for ICI response in NSCLC, stratified by histological subtype (adenocarcinoma vs. squamous cell carcinoma), smoking status (current/former vs. never smokers), and co-occurring driver mutations (KRAS, STK11, KEAP1, TP53). The analyses reveal that predictive performance varies significantly across subgroups, with notably lower predictive accuracy in squamous histology and STK11-mutant tumors. These findings are relevant to potential subgroup analyses of CLARITY-LUNG data that may need to be pursued if the final trial results require subpopulation-specific performance claims or if the overall population results remain below pre-specified thresholds, necessitating identification of patient subgroups in which GXP-47 demonstrates clinically meaningful predictive performance.
IV. Category C: Clinical Utility (Publications 21–30)
Purpose: Publications in this category demonstrate the clinical utility of genomic expression-based predictive testing in guiding ICI therapy decisions in NSCLC. Clinical utility evidence addresses the question of whether test results, when communicated to clinicians, change treatment decisions in ways that improve patient outcomes, reduce adverse events, or avoid unnecessary or futile therapy. This evidence is critical to the MolDx technical assessment, as Ridgeline Administrative Services, LLC requires demonstration that a test's results are "reasonably expected to change clinical management and improve patient outcomes" as a condition of favorable technical assessment. Publications in this category are referenced primarily in Section 4 (Clinical Utility Evidence) of the MolDx Technical Assessment Dossier.
Publication 21. Citation: Aggarwal C, Thompson JC, Chien AL, et al. "Impact of multi-gene expression profiling on treatment selection for advanced NSCLC: a prospective decision-impact study." Annals of Oncology. 2023;34(9):1089–1103.
Relevance Category: C — Clinical Utility
Annotation: This prospective decision-impact study enrolled 428 patients with newly diagnosed advanced NSCLC and assessed whether the availability of multi-gene expression profiling results changed the treating oncologist's pre-test treatment plan. The study employed a pre-test/post-test design in which oncologists documented their intended treatment (ICI vs. chemotherapy vs. combination) both before and after receiving genomic profiling results. The results demonstrated that treatment plans were modified in 34.1% of cases (146 of 428) upon receipt of gene expression profiling data, with the most common modification being a switch from empiric ICI therapy to platinum-based chemotherapy in patients with low predicted likelihood of ICI response. This publication provides direct clinical utility evidence supporting the argument that OncoPrecise GXP-47 TRI scoring would meaningfully influence clinical decision-making in the target patient population.
Publication 22. Citation: Naidoo J, Wang X, Woo KM, et al. "Avoiding futile immunotherapy in advanced NSCLC: the potential role of predictive genomic biomarkers in reducing treatment-related adverse events." Journal of Clinical Oncology. 2022;40(15):1678–1692.
Relevance Category: C — Clinical Utility
Annotation: This publication quantifies the adverse event burden associated with ICI therapy in patients who ultimately do not respond to treatment, analyzing pooled data from five clinical trials encompassing 3,247 patients with advanced NSCLC. The authors report that among non-responders, 31.8% experienced grade 3 or higher immune-related adverse events (irAEs), including pneumonitis (8.4%), hepatitis (5.1%), and colitis (4.7%), with associated healthcare costs and quality-of-life decrements. The study argues that biomarker-guided treatment selection could reduce the incidence of futile ICI exposure and its attendant adverse events. This publication directly supports OncoPrecise GXP-47's intended use in identifying patients with a Low likelihood of ICI response (TRI < 40) who may benefit from alternative first-line therapy, thereby avoiding exposure to the risks of immunotherapy without commensurate therapeutic benefit.
Publication 23. Citation: Fryback DG, Trosman JR, Weldon CB, et al. "Clinical utility frameworks for molecular diagnostic tests in oncology: MolDx program requirements and evidentiary standards." Genetics in Medicine. 2022;24(3):567–580.
Relevance Category: C — Clinical Utility
Annotation: This publication provides a detailed description of the clinical utility evidentiary standards required by the MolDx program administered by Ridgeline Administrative Services, LLC, synthesizing information from published MolDx guidance documents, LCD precedents, and interviews with MolDx program officials. The authors present a tiered evidentiary framework that distinguishes between Level I evidence (prospective randomized controlled trials demonstrating improved outcomes), Level II evidence (prospective decision-impact or observational studies), and Level III evidence (chain-of-evidence approaches linking analytical validity, clinical validity, and clinical utility through indirect evidence). This framework is directly applicable to the structure and presentation of the clinical utility section of the MolDx Technical Assessment Dossier and has informed the organization of evidence in the present bibliography.
Publication 24. Citation: Pennell NA, Arcila ME, Gandara DR, et al. "Physician survey on the adoption of gene expression-based predictive testing for immunotherapy in lung cancer." JCO Precision Oncology. 2023;7:e2300142.
Relevance Category: C — Clinical Utility
Annotation: This publication reports results from a national survey of 612 practicing oncologists assessing their knowledge of, attitudes toward, and willingness to adopt gene expression-based predictive tests for guiding ICI therapy decisions in lung cancer. The survey found that 71.2% of respondents indicated they would order a validated gene expression-based predictive test if it were available and covered by insurance, while 24.3% indicated conditional willingness dependent on strength of clinical evidence and turnaround time. These adoption data support the projected test utilization rates underlying GDT's commercial volume projections, which assume Year 1 test volumes of approximately 8,500 tests and Year 3 volumes of approximately 22,000 tests based on estimated market penetration in the addressable NSCLC population.
Publication 25. Citation: Reck M, Remon J, Planchard D, et al. "Patient outcomes associated with biomarker-guided versus empiric selection of first-line immunotherapy in advanced NSCLC." The Lancet Respiratory Medicine. 2023;11(5):412–426.
Relevance Category: C — Clinical Utility
Annotation: This comparative outcomes study analyzes data from a large international registry of advanced NSCLC patients, comparing progression-free survival and overall survival between patients whose first-line ICI therapy was selected using comprehensive biomarker testing (PD-L1, TMB, and gene expression profiling) and patients whose ICI therapy was selected on an empiric basis with PD-L1 testing alone. The biomarker-guided cohort demonstrated a statistically significant improvement in 12-month PFS (48.7% vs. 36.2%, HR 0.72, p = 0.003) and a trend toward improved overall survival. This publication provides clinical utility evidence directly relevant to the intended use of OncoPrecise GXP-47, supporting the hypothesis that multi-analyte biomarker-guided treatment selection improves clinical outcomes relative to standard-of-care approaches.
Publication 26. Citation: Trosman JR, Weldon CB, Douglas MP, et al. "Clinical utility of genomic diagnostics in oncology: evidence requirements for Medicare coverage under the MolDx program." Health Affairs. 2021;40(7):1102–1111.
Relevance Category: C — Clinical Utility
Annotation: This publication reviews the evidentiary hierarchy employed by the MolDx program in evaluating clinical utility evidence for genomic diagnostic tests in oncology, distinguishing between direct evidence derived from randomized controlled trials, indirect evidence from decision-impact studies and observational analyses, and chain-of-evidence approaches that link analytical validity, clinical validity, and clinical utility through a logical chain of reasoning. The authors note that the MolDx program has, in certain cases, accepted chain-of-evidence approaches when direct prospective evidence is not yet available, provided that each link in the chain is supported by robust data. This publication is relevant to strategic considerations regarding the sufficiency of GXP-47's current evidence package, particularly in light of the below-threshold interim results from the CLARITY-LUNG trial (Publication 10).
Publication 27. Citation: Cristescu R, Mogg R, Ayers M, et al. "The Therapy Response Index concept: integrating multiple gene expression signals into a composite clinical decision score." Nature Reviews Clinical Oncology. 2022;19(8):508–522.
Relevance Category: C — Clinical Utility
Annotation: This review article discusses the methodological and clinical rationale for constructing composite clinical decision scores from multi-gene expression data, as opposed to reporting individual gene expression values or single-pathway scores. The authors examine multiple approaches — including weighted linear combinations, machine learning-derived classifiers, and ensemble methods — and evaluate the trade-offs between interpretability, predictive accuracy, and clinical actionability. The composite scoring approach described in this publication is directly relevant to the proprietary TRI algorithm underlying OncoPrecise GXP-47, which integrates expression data from all 47 genes in the panel into a single, clinically actionable 0–100 score with three-tier risk stratification.
Publication 28. Citation: Marabelle A, Fakih M, Lopez J, et al. "Real-world clinical utility of companion and complementary diagnostics for immune checkpoint inhibitors: a registry-based analysis." European Journal of Cancer. 2023;182:114–129.
Relevance Category: C — Clinical Utility
Annotation: This registry-based analysis examines the real-world utilization patterns and clinical impact of biomarker testing associated with ICI therapy, including PD-L1 IHC companion diagnostics (22C3 pharmDx for pembrolizumab, 28-8 pharmDx for nivolumab, SP142 for atezolizumab) and complementary diagnostic tests. The study analyzes data from over 18,000 patients across 142 oncology practices and reports that biomarker testing rates vary substantially by practice setting, with community oncology practices demonstrating lower testing rates than academic centers. The findings contextualize GXP-47 within the existing landscape of companion and complementary diagnostics for checkpoint inhibitors and provide data relevant to projected market adoption and testing volume assumptions.
Publication 29. Citation: Singal G, Miller PG, Agarwala V, et al. "Treatment modification rates following multi-gene genomic testing in advanced lung cancer: evidence from a large integrated health system." JAMA Oncology. 2022;8(4):512–521.
Relevance Category: C — Clinical Utility
Annotation: This retrospective cohort study analyzes treatment modification rates attributable to multi-gene genomic testing in a population of 2,847 advanced lung cancer patients treated within a large integrated health system spanning 23 facilities. The study reports that 28.6% of patients experienced a change in their initially planned treatment regimen following receipt of multi-gene genomic profiling results, with the most frequent modifications involving the addition or withdrawal of immunotherapy (14.3%) and enrollment in biomarker-selected clinical trials (8.9%). This publication provides real-world clinical utility evidence supporting the argument that genomic test results — including results from gene expression-based predictive assays analogous to OncoPrecise GXP-47 — meaningfully alter clinical decision-making in the advanced lung cancer treatment setting.
Publication 30. Citation: Kerr KM, Bubendorf L, Edelman MJ, et al. "Clinical utility of genomic profiling in non-small-cell lung cancer: a consensus statement from the International Consortium for Lung Cancer Genomics." Lancet Oncology. 2023;24(6):e231–e248.
Relevance Category: C — Clinical Utility
Annotation: This consensus statement, authored by an international panel of 34 experts convened under the auspices of the International Consortium for Lung Cancer Genomics, provides a comprehensive endorsement of the clinical utility of genomic profiling — including gene expression-based predictive testing — in NSCLC treatment decision-making. The statement recommends that multi-gene genomic profiling be considered for all patients with advanced NSCLC at the time of diagnosis and identifies prediction of ICI therapy response as one of the highest-priority clinical applications for emerging genomic tests. This expert consensus statement provides authoritative backing for the intended clinical use of OncoPrecise GXP-47 and may be referenced in discussions with the MolDx Technical Assessment Director and in any future LCD application to Cascade Fiscal Intermediaries, LLC.
V. Category D: Health Economics (Publications 31–37)
Purpose: Publications in this category support the health economic analysis prepared by Dr. Nathan Ostroff, PhD, MS, Principal Consultant, Larkfield Health Economics, LLC, for inclusion in Section 5 (Health Economic Analysis) of the MolDx Technical Assessment Dossier. These publications address cost-effectiveness modeling, budget impact analysis, the economic burden of treatment failure in advanced NSCLC, health economic evaluation frameworks accepted by CMS and the MolDx program, value-based pricing and crosswalk/gapfill methodologies for proprietary genomic tests, cost consequences of testing turnaround time, and Medicare reimbursement trends for NGS-based oncology diagnostics.
Publication 31. Citation: Garrison LP Jr, Pauly MV, Neumann PJ, et al. "Cost-effectiveness of gene expression-based predictive testing for immune checkpoint inhibitor therapy in advanced NSCLC: a decision-analytic model." Value in Health. 2023;26(3):345–358.
Relevance Category: D — Health Economics
Annotation: This publication presents a decision-analytic model evaluating the cost-effectiveness of gene expression-based predictive testing compared to standard-of-care biomarker testing (PD-L1 IHC alone) for ICI therapy selection in patients with advanced NSCLC, adopting a Medicare payer perspective over a three-year time horizon. The model incorporates costs of testing, first-line therapy (ICI vs. chemotherapy), adverse event management, second-line therapy, and end-of-life care, and reports results in terms of incremental cost per quality-adjusted life year (QALY) gained. At a test cost of $3,500, the model yields an incremental cost-effectiveness ratio (ICER) of $42,300 per QALY gained, well below the commonly cited willingness-to-pay threshold of $100,000 per QALY. This publication provides the methodological template for the cost-effectiveness analysis prepared by Larkfield Health Economics, LLC, and incorporated into the MolDx Technical Assessment Dossier.
Publication 32. Citation: Sullivan SD, Watkins J, Engstrom P, et al. "Budget impact analysis of predictive genomic testing for immunotherapy in a Medicare population with advanced NSCLC." Journal of Managed Care & Specialty Pharmacy. 2023;29(8):891–904.
Relevance Category: D — Health Economics
Annotation: This publication presents a budget impact model analyzing the financial consequences of adopting predictive genomic testing for ICI therapy selection within a hypothetical Medicare beneficiary population of 500,000 members with an assumed advanced NSCLC incidence rate consistent with SEER data. The model projects net budget savings over a five-year adoption horizon, driven primarily by avoidance of costly ICI therapy in patients predicted to be non-responders and reduction in the management costs of immune-related adverse events. This publication is directly relevant to GDT's projected Medicare test volume, which is estimated to represent 62% of total test volume based on the epidemiology of advanced NSCLC in the Medicare-eligible population, and to the target Medicare reimbursement rate of $3,850 per test that underlies GDT's financial projections.
Publication 33. Citation: Mantia CM, Buchbinder EI, McDermott DF, et al. "The economic burden of treatment failure in advanced non-small-cell lung cancer: implications for the value of predictive diagnostics." Cancer Economics and Outcomes. 2022;4(2):112–128.
Relevance Category: D — Health Economics
Annotation: This publication quantifies the economic burden of ICI treatment failure in patients with advanced NSCLC, using administrative claims data from a nationally representative sample of commercially insured and Medicare Advantage enrollees. The authors report that patients who fail first-line ICI therapy incur mean incremental healthcare costs of $87,400 over the 12 months following treatment failure, driven by the costs of managing immune-related adverse events ($18,200), administration of second-line chemotherapy ($32,600), hospitalizations ($24,100), and supportive care ($12,500). These findings support the value proposition that OncoPrecise GXP-47 testing can reduce overall healthcare expenditures by prospectively identifying patients unlikely to respond to ICI therapy and directing them to more appropriate alternative first-line treatment strategies.
Publication 34. Citation: Neumann PJ, Cohen JT, Ollendorf DA, et al. "Health economic evaluation frameworks for molecular diagnostics: alignment with CMS national coverage and MolDx program standards." Medical Decision Making. 2022;42(5):623–638.
Relevance Category: D — Health Economics
Annotation: This methodological publication reviews the health economic evaluation frameworks accepted by CMS in the context of national coverage determinations and by the MolDx program in the context of technical assessments for molecular diagnostic tests. The authors discuss the distinction between cost-effectiveness analysis (CEA), cost-utility analysis (CUA), budget impact analysis (BIA), and cost-consequence analysis (CCA), and identify the analytic perspectives, time horizons, and discount rates that are most consistent with CMS decision-making preferences. This publication informs the structure and analytical approach of the HEOR analysis prepared by Dr. Ostroff and Larkfield Health Economics, LLC, for inclusion in the MolDx Technical Assessment Dossier, ensuring alignment with the methodological expectations of the Ridgeline technical assessment review team.
Publication 35. Citation: Deverka PA, Douglas MP, Phillips KA, et al. "Value-based pricing for proprietary genomic diagnostic tests: crosswalk methodology and premium justification." Journal of Health Economics and Outcomes Research. 2023;10(1):34–49.
Relevance Category: D — Health Economics
Annotation: This publication discusses the crosswalk and gapfill pricing methodologies employed under Medicare's Clinical Laboratory Fee Schedule (CLFS) for the establishment of reimbursement rates for novel proprietary genomic tests. The authors examine the selection of appropriate comparator tests, the criteria for justifying pricing premiums or discounts relative to comparators, and the role of clinical evidence and health economic data in supporting reimbursement rate applications. This publication is directly relevant to the reimbursement rate analysis prepared by Calderwood & Harkness LLP, which identifies three crosswalk comparators — the GeneSight Onco-48 assay by Elara Genomic Sciences (PLA Code 0250U, Medicare rate: $3,742/test), CPT code 81455 (Medicare rate: $2,919/test), and TumorMap Pro by Marlowe Asset Management Molecular Diagnostics (PLA Code 0239U, Medicare rate: $4,206/test) — and justifies the target Medicare reimbursement rate of $3,850 per test, representing a 6.28% premium over the $3,622.33 weighted average of the three comparators.
Publication 36. Citation: Roberts MC, Clyne M, Kennedy AE, et al. "Cost consequences of delayed cancer treatment due to biomarker testing turnaround time: a modeling study." Cancer Medicine. 2022;11(18):3498–3512.
Relevance Category: D — Health Economics
Annotation: This publication presents a simulation model estimating the clinical and economic consequences of treatment delays attributable to biomarker testing turnaround time in patients with advanced solid tumors, including NSCLC. The model evaluates turnaround times ranging from 5 to 28 calendar days and estimates the incremental cost and QALY impact of each day of treatment delay. The findings indicate that treatment delays beyond 14 calendar days are associated with measurable clinical detriment and incremental cost, while delays within a 7–10 day window have minimal impact. This publication is relevant to GDT's single-site reference laboratory operational model, which projects a specimen-to-report turnaround time of 10–12 business days for OncoPrecise GXP-47, and to the assessment of whether this turnaround time is clinically and economically acceptable relative to the anticipated benefits of predictive biomarker testing.
Publication 37. Citation: Phillips KA, Deverka PA, Hooker GW, et al. "Medicare reimbursement trends for NGS-based oncology diagnostics: a five-year analysis of PLA and CPT code pricing." Genetics in Medicine. 2023;25(11):100949.
Relevance Category: D — Health Economics
Annotation: This publication analyzes Medicare reimbursement trends for NGS-based oncology diagnostic tests over a five-year period (2018–2023), tracking pricing movements for both PLA-coded proprietary tests and generic CPT-coded molecular pathology procedures. The analysis demonstrates that PLA-coded tests have maintained more stable reimbursement rates compared to generic CPT codes, which have experienced progressive rate compression under the CLFS payment methodology. The findings provide important market context for the pricing of OncoPrecise GXP-47 and support GDT's strategy of pursuing a unique PLA code rather than relying on existing CPT codes, as well as the crosswalk analysis positioning the test relative to comparable PLA-coded assays in the oncology molecular diagnostics space.
VI. Category E: Background Literature — ICI Therapy in NSCLC (Publications 38–43)
Purpose: Publications in this category provide the foundational scientific and clinical background on immune checkpoint inhibitor therapy in advanced non-small-cell lung cancer, including the mechanisms of action of anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents; approved indications and pivotal clinical trial outcomes; limitations of currently available predictive biomarkers; epidemiology and disease burden of advanced NSCLC in the United States; and emerging biomarker strategies. These publications establish the clinical context and medical necessity for OncoPrecise GXP-47 and are referenced primarily in the Introduction and Test Description sections of the MolDx Technical Assessment Dossier.
Publication 38. Citation: Ribas A, Wolchok JD, Hodi FS, et al. "Immune checkpoint inhibitors in advanced non-small-cell lung cancer: mechanisms of action and clinical development milestones." New England Journal of Medicine. 2020;383(14):1358–1375.
Relevance Category: E — Background Literature
Annotation: This comprehensive review article describes the mechanisms of action of the three principal classes of immune checkpoint inhibitors — anti-PD-1 (pembrolizumab, nivolumab), anti-PD-L1 (atezolizumab, durvalumab), and anti-CTLA-4 (ipilimumab) — and traces the pivotal clinical trials that led to FDA approvals for their use in advanced NSCLC, including Tidewater Data Systems-024, Tidewater Data Systems-042, CheckMate-227, and IMpower110. The article discusses the transformative impact of ICI therapy on survival outcomes in advanced NSCLC while noting that only a minority of patients (approximately 20–35%) achieve durable clinical benefit. This publication provides the foundational clinical context for OncoPrecise GXP-47's intended use population — patients with Stage IIIB/IV NSCLC — and establishes the clinical need for improved tools to predict which patients will benefit from ICI therapy.
Publication 39. Citation: Paz-Ares L, Ciuleanu TE, Cobo M, et al. "First-line immune checkpoint inhibitor therapy versus platinum-based chemotherapy in advanced NSCLC: a network meta-analysis." The Lancet Oncology. 2022;23(3):367–382.
Relevance Category: E — Background Literature
Annotation: This network meta-analysis synthesizes efficacy data from 18 randomized controlled trials comparing ICI therapy to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC, stratified by PD-L1 expression level, histological subtype, and performance status. The analysis demonstrates a clear efficacy advantage of ICI therapy in patients with PD-L1 TPS ≥ 50% (HR for overall survival 0.62, 95% CI 0.55–0.70) but an attenuated and non-significant benefit in patients with PD-L1 TPS < 1% (HR 0.91, 95% CI 0.78–1.06). These findings underscore the critical importance of biomarker-guided patient selection for ICI therapy and establish the clinical rationale for developing multi-analyte predictive tools that can more precisely identify patients who will and will not benefit from immunotherapy.
Publication 40. Citation: Hirsch FR, McElhinny A, Stanforth D, et al. "Limitations of PD-L1 as a predictive biomarker for immune checkpoint inhibitor response in NSCLC: a critical appraisal." Journal of Thoracic Oncology. 2021;16(7):1127–1142.
Relevance Category: E — Background Literature
Annotation: This publication critically appraises the limitations of PD-L1 tumor proportion score (TPS) as a standalone predictive biomarker for ICI response in NSCLC. The authors identify several well-documented shortcomings, including substantial inter-assay variability across the four commercially available PD-L1 IHC assays (22C3, 28-8, SP142, SP263), intra-tumoral spatial heterogeneity of PD-L1 expression, temporal variability with treatment exposure, and the imperfect predictive performance evidenced by the fact that a substantial proportion of PD-L1-high patients do not respond to ICI therapy while some PD-L1-low or PD-L1-negative patients achieve durable benefit. This publication establishes the unmet clinical need for improve